Establishing Pompe Disease Newborn Screening: The Role of Industry

Abstract

by Joan M. Keutzer
Int. J. Neonatal Screen. 2020, 6(3), 55; https://doi.org/10.3390/ijns6030055 - 15 FEB 2022
Cited by 6 | Viewed by 3065
Abstract
When clinical trials for enzyme replacement therapy for Pompe disease commenced, a need for newborn screening (NBS) for Pompe disease was recognized. Two methods for NBS for Pompe disease by measuring acid α-glucosidase in dried blood spots on filter paper were developed in an international collaborative research effort led by Genzyme. Both methods were used successfully in NBS pilot programs to demonstrate the feasibility of NBS for Pompe disease. Since 2009, all babies born in Taiwan have been screened for Pompe disease. Pompe disease was added to the Recommended Uniform (Newborn) Screening Panel in the United States in 2015. NBS for Pompe disease is possible because of the unprecedented and selfless collaborations of countless international experts who shared their thoughts and data freely with the common goal of establishing NBS for Pompe disease expeditiously. Full article
(This article belongs to the Special Issue Newborn Screening for Pompe Disease)
8 pages, 187 KiB
Open AccessReview